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Abstract
Extending the scope of biocatalysis to important non-natural reactions such as olefin 
cyclopropanation will open new opportunities for replacing multi-step chemical syntheses of 
pharmaceutical intermediates with efficient, clean, and highly selective enzyme-catalyzed 
processes. In this work, we engineered the truncated globin of Bacillus subtilis for the synthesis of 
a cyclopropane precursor to the antithrombotic agent ticagrelor. The engineered enzyme catalyzes 
the cyclopropanation of 3,4-difluorostyrene with ethyl diazoacetate on a preparative scale to give 
ethyl-(1R, 2R)-2-(3,4-difluorophenyl)-cyclopropanecarboxylate in 79% yield, with very high 
diastereoselectivity (>99% dr) and enantioselectivity (98% ee), enabling a single-step biocatalytic 
route to this pharmaceutical intermediate.
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Ticagrelor (1) is a P2Y12 antagonist developed by AstraZeneca under the trade name 
Brilinta® (Figure 1). It was approved by the FDA in 2011 for the prevention of platelet 
aggregation after the occurrence of a thrombotic event.1 Sales in 2015 were $619 million 
and are projected to go as high as $3.5 billion by 2023.2–3 Most of the patented syntheses of 
ticagrelor use a key chiral cyclopropane intermediate, (1R,2S)-2-(3,4-
difluorophenyl)cyclopropan-1-amine (2). The various methods reported for the preparation 
of this building block are lengthy, requiring resolutions, chiral auxiliaries or expensive 
catalysts to obtain the desired enantiomer.4–18 Recently, there has been a push to use 
biocatalysts in order to decrease toxic wastes and make pharmaceutical production 
‘greener’.19–20 A notable example of success in the development of biocatalytic alternatives 
can be found in Merck’s production of sitagliptin, used to treat Type 2 diabetes. Directed 
evolution was used to engineer a transaminase to synthesize the drug under industrial 
process conditions; the result was a biocatalytic process with 10–13% higher product yield, 
a 19% reduction in overall waste, and elimination of all heavy metals.21 Similarly, 
biocatalysis can potentially offer very high selectivity and environmentally friendly process 
conditions for the synthesis of ticagrelor. Turner and coworkers recently examined three 
complementary biocatalytic routes for the preparation of cyclopropylamine 2.22 They 
demonstrated that a ketoreductase could convert 1-(3,4-difluorophenyl)-3-nitropropan-1-one 
to the corresponding enantiopure alcohol, a building block that could lead to 
cyclopropylamine 2 in two to three steps; alternatively, a lipase or amidase could be used for 
kinetic resolution of a racemic mixture of cyclopropyl ester or amide to yield chiral 
precursors suitable for the preparation of 2.
Recent reports from our laboratory23–24 and others25–26 have shown that heme proteins can 
catalyze the cyclopropanation of various olefins using diazo compounds. Cyclopropyl motifs 
are present in many bioactive and synthetic compounds and serve as versatile intermediates 
in organic synthesis.27–28 The proteins reported to catalyze olefin cyclopropanation have 
proven to be amenable to directed evolution for increased activity and to obtain the desired 
product with high diastereo- and enantioselectivity in a single step: for example, Wang et al. 
engineered a cytochrome P450 to produce the chiral cyclopropane core of 
levomilnacipran.24
Here we report an enantioselective synthesis of the chiral cyclopropane core of ticagrelor 
(Figure 1C) using a whole-cell biocatalyst expressing an engineered heme protein derived 
from Bacillus subtilis group II truncated hemoglobin (UniProt ID: O31607).29 This 
engineered enzyme catalyzes the cyclopropanation of commercially available 3,4-
difluorostyrene (DFS, 3) using ethyl diazoacetate (EDA, 4) to provide one-step access to 
ethyl-(1R,2R)-2-(3,4-difluorophenyl)-cyclopropanecarboxylate (R,R)-5, an ester precursor 
of the ticagrelor cyclopropylamine 2, with excellent selectivity for the desired stereoisomer.
We began by screening various heme proteins for their ability to catalyze the reaction of 
DFS (3) with EDA (4) to produce the ticagrelor cyclopropyl ester (R,R)-5. Most of the 
proteins tested, such as the H64V V68A variant of sperm whale myoglobin,25 gave 
primarily the opposite enantiomer of the desired precursor. Three proteins gave an enantio-
enriched product with the desired (R,R)-configuration:
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B. subtilis group II truncated globin, Hydrogenobacter thermophilus cytochrome c M59A 
Q62A, and Bacillus megaterium P450-BM3 T268A C400H, which gave product in 34, 44, 
and 8 % ee, respectively. Mutagenesis was performed on all three proteins, but substantial 
improvement in enantioselectivity was only observed with variants of the B. subtilis group II 
truncated globin. The directed evolution strategy we used to optimize the performance of 
this protein is outlined below. B. subtilis group II truncated globin is a small (132 residues, 
15 kDa) monomeric protein with very high oxygen affinity and a published crystal structure 
(PDB ID: 1UX8).29 We hypothesized that iron-carbenoid formation occurred in the distal 
region of the heme and that mutation of amino acid residues in this nascent “active site” 
could improve its catalytic performance. Bordeaux et al. showed that mutations at H64 and 
V68 in sperm whale myoglobin could tune the stereoselectivity of the cyclopropanation 
reaction between ethyl diazoacetate and styrene.25 We chose the analogous residues in B. 
subtilis truncated globin (T45 and Q49, based on a sequence alignment, see Supplemental 
Information) and targeted those two sites for mutagenesis (Figure 2). The two residues were 
mutated simultaneously to one of three residues (leucine, phenylalanine, and alanine) in an 
attempt to find variants that would improve the yield and enantioselectivity of the reaction. 
The T45A Q49A double mutant stood out as highly selective, yielding the desired product in 
95% ee with a yield of 57%. Modeling with a Dunbrack rotamer library30 suggests that the 
amount of space in the nascent active site is increased when the polar and larger threonine 
and glutamine are mutated to smaller, non-polar alanine.
Truncated globins natively bind oxygen and do not have an active site for catalysis; we 
attribute the observed improvement in selectivity to the formation of a binding pocket on the 
distal side of the heme, which presumably binds the substrates in an orientation that favors 
formation of the desired product. To further improve enantioselectivity, site-saturation 
mutagenesis was performed at position A45, and the distal heme ligand Y25. While 
mutations at A45 failed to improve enantioselectivity, screening of the Y25 library led to the 
discovery of variant Y25L T45A Q49A, which maintained the yield of the parent protein 
while affording >99% dr and 97% ee at 20 mM DFS and 40 mM EDA.
To further increase product yield, the Y25L T45A Q49A variant was expressed in two E. 
coli BL21 derivative cell lines C41(DE3) and C43(DE3), which have been optimized to 
overexpress mildly toxic proteins.31 Both C41(DE3) and C43(DE3) cells expressing the 
Y25L T45A Q49A variant showed increases in enantio- and diastereoselectivity through 
improved expression of the recombinant protein. The engineered protein now effectively 
outcompetes the small amount of background reaction from the cells (which produces 
racemic product).32 The C43(DE3) line displayed the highest diastereo- and 
enantioselectivity (>99% dr and ee) at 20 mM DFS/40 mM EDA and was selected for use in 
preparative-scale reactions.
Preparative scale (0.4 mmol, 20 mL) reactions were performed anaerobically23–24 using 
whole-cell catalyst (OD600=80) and 20 mM DFS/40 mM EDA (Figure 3). Initially these 
reactions were done with simultaneous addition of the bacterial catalyst and reagents, which 
gave high selectivity for the desired product, but only ~50% yield. After testing a range of 
reaction conditions, we found that slow addition of the whole-cell catalyst and EDA (4) 
solutions to DFS (3) over the course of 3 hours gave the ticagrelor cyclopropyl ester (R,R)-5 
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as virtually a single isomer (>99% dr, 98% ee) in 79% yield (see Supporting Information). It 
is likely that slow addition slows down the formation of EDA dimer and reduces catalyst 
inactivation by carbene transfer to the protein (heme cofactor and nucleophilic side chains) 
rather than the DFS, an inactivation mechanism we recently analyzed in detail in another 
cyclopropanation enzyme.33
This work has generated an efficient, stereoselective, and potentially low-cost bacterial 
biocatalyst for producing the cyclopropane precursor to the antithrombotic agent ticagrelor. 
The ester product of the biocatalytic reaction (R,R)-5, can be converted easily to the amine 
ticagrelor precursor 2 via ammonolysis followed by Hofmann rearrangement16 of the 
corresponding amide or a Curtius rearrangement9 on the corresponding acyl azide. This 
work has also demonstrated how directed evolution can rapidly optimize a newly discovered 
enzyme activity, olefin cyclopropanation, to achieve desired product selectivity and yield. 
With careful process optimization, processes based on biological catalysts such as reported 
here can continue to replace far less environmentally friendly methods for producing 
pharmaceutical intermediates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Structure of ticagrelor 1. (B) The cyclopropyl ester precursor 5 can be converted to the 
cyclopropylamine precursor 2 by making the acyl azide and performing a Curtius 
rearrangement9 or via ammonolysis followed by Hofmann rearrangement16 of the 
corresponding amide. (C) Cyclopropanation of 3,4-difluorostyrene (3) with ethyl 
diazoacetate (4) catalyzed by engineered heme protein makes the cyclopropyl ester 5.
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Figure 2. 
Positions of the Y25, T45, and Q49 residues near the heme iron in the B. subtilis wild-type 
protein (PDB ID: 1UX8).
Hernandez et al. Page 8
ACS Catal. Author manuscript; available in PMC 2017 November 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
(A) Enantioselectivity of the cyclopropanation reaction catalyzed by various B. subtilis 
variants. Reaction conditions: OD600=60, 20 mM DFS/40 mM EDA. (B) Enantioselectivity 
of the cyclopropanation reaction catalyzed by B. subtilis T45A Q49A Y25L expressed in 
various E. coli strains. Reaction conditions: OD600=60, 20 mM DFS/40 mM EDA. The error 
bars represent standard deviation of % ee (trans) for the reactions run in triplicate.
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